KLF9 and ovarian carcinoma: Overall, our data indicate that TPD52 and miR-223 are greater in ovarian cancer patients than in healthy persons, but the expression of KLF9 and PKCε is lower (0.2 ± 5.7) in ovarian cancer patients than in healthy individuals (Fig. 4).